by circulating antibodies to a 64,000-M r islet cell antigen identified as glutamic acid decarboxylase (GAD). We describe a radioimmunoprecipitation assay with GAD isolated from pig brain. The sera tested were from 80 patients with IDDM including 26 with disease of recent onset and 54 with disease of longer duration (3-42 yr), 20 with non-insulin-dependent diabetes mellitus (NIDDM), and 55 nondiabetic subjects. Conventional assays for islet cell cytoplasmic antibodies were performed concurrently. The level of antibody in serum was expressed in units based on percentage reactivity of a standard reference serum. The frequency of antibody to GAD in IDDM was 69% in short-duration cases and 59% in longduration cases. The latter was substantially higher than the frequency of islet cell cytoplasmic antibody. Antibodies to GAD were elevated (means±3 SD) in 5% NIDDM cases and in none of the nondiabetic subjects. A simple laboratory test with a defined autoantigen has substantial implications for population screening and early diagnosis of IDDM and for better understanding of its pathogenesis. Diabetes 41:548-51, 1992 D iabetes mellitus is a heterogeneous disorder. Insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) are subtyped physiologically according to patients' dependence for survival on treatment with insulin (1). IDDM is attributed to autoimmunity (2) (5) to establish the coidentity of their 64,000-M r antigen and GAD. In this study, we describe a high frequency of positive results by radioimmunoprecipitation assay with IDDM sera and a GAD preparation from pig brain and propose that detection of antibodies to GAD may be a useful diagnostic test as an autoimmune marker associated with IDDM.
D
iabetes mellitus is a heterogeneous disorder. Insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) are subtyped physiologically according to patients' dependence for survival on treatment with insulin (1) . IDDM is attributed to autoimmunity (2) by reason of disease associations, autoantibodies to pancreatic islet cell antigens, similarities with animal models of IDDM and HLA linkages. The disease-relevant autoantigen or antigens in IDDM include a 64,000-M r protein demonstrable by immunoprecipitation from pancreatic islets (3) but hitherto unidentified because of low abundance and assay difficulties. Immunoassay for antibody to the 64,000-M r antigen indicated that it was a specific marker for IDDM and preceded symptomatic onset of disease (4) . The recognition in cases of the Stiff Man syndrome of coexisting IDDM and a neural antigen of 64,000-65,000 M r identified as glutamic acid decarboxylase (GAD) led Baekkeskov et al. (5) to establish the coidentity of their 64,000-M r antigen and GAD. In this study, we describe a high frequency of positive results by radioimmunoprecipitation assay with IDDM sera and a GAD preparation from pig brain and propose that detection of antibodies to GAD may be a useful diagnostic test as an autoimmune marker associated with IDDM.
RESEARCH DESIGN AND METHODS
Sera were tested from 80 patients with IDDM, 20 patients with NIDDM, 3 with unclassified diabetes, and 55 nondiabetic blood donors with no known first-degree relatives with diabetes. The diagnosis of IDDM or NIDDM was made according to the National Diabetes Data Group criteria for the classification of diabetes mellitus (6) . Thus, our patients with IDDM were nonobese and presented symptoms such as polydipsia, polyuria, and weight loss; most patients became diabetic before 40 yr of age, and all required daily insulin injections to control blood glucose concentrations. Our patients with NIDDM were mostly obese and age at onset was >40 yr, and in almost all patients blood glucose concentrations were adequately controlled by diet or diet and oral hypoglycemic drugs. The 3 unclassified patients presented as NIDDM with blood glucose concentrations adequately controlled by diet and subsequent oral hypoglycemic drugs for 4-7 yr before becoming insulin dependent with low C-pep- tide levels. Of the 80 patients with IDDM, 26 were tested within 1 yr of initial diagnosis, including 11 within 1 mo of diagnosis. Fifty-four were tested 3-42 yr after diagnosis; of these, the mean ± SD duration of disease was 16 ± 9 yr. All laboratory assays were performed on coded sera so that the technician was unaware of the source of the serum. Details of the patient groups are shown in Table 1 .
Islet cell antibody tests.
Islet cell antibodies (ICAs) were assessed by indirect immunofluorescence on cryostat sections of pancreas from a blood group O donor as previously described (7). Results were expressed in Juvenile Diabetes Foundation (JDF) units, and a positive result was defined as >5 JDF U. Preparation of pork GAD. Fresh pig brain was homogenized in ice-cold water containing 0.1 mM 2-aminoethylisothiouronium bromide (AET), 5 mM EDTA, 20 |xM pyridoxal-5'-phosphate (PLP), 0.1 mM phenylmethylsulfonylfluoride (PMSF), and 20 |xM leupeptin. The supernatant was clarified by successive centrifugations for 45 min at 4°C at 20,000 and 100,000 g (8) . To purify GAD, the supernatant was passed over an affinity column in which antibody to GAD-1 (9) was coupled to Sepharose CL-4B (Pharmacia, Uppsala, Sweden) with cyanogen bromide according to the supplier's instructions. This antibody binds to both isoforms of GAD. GAD was eluted with 50 mM KH 2 PO 4 , 10 mM diethylamine, 20 mM glutamic acid, 1 mM AET, 20 JJLM PLP, pH 10.5, collected as 2-ml fractions in 100 |xl 1 M NaH 2 PO 4 (pH 6.9) containing 20 (xM PLP. Fractions were assayed by gel electrophoresis and enzyme analysis, dialyzed into 20 mM KH 2 PO 4 (pH 7.2) containing 20 jxM PLP, and stored at -20°C in 50% glycerol. GAD enzyme assay. GAD catalyzes the production of T-aminobutyric acid (GABA) from glutamate. The activity of the enzyme was measured by a method modified from Chude and Wu (10) that depends on the binding of glutamate but not GABA to the ion-exchange resin AG1-X8 (Bio-Rad). The reaction mixture contained GAD in 50 mM KH 2 PO 4 with 1 mM 2-mercaptoethanol, 1 mM PMSF, 0.2 mM PLP, 1 mM AET, and 10 mM glutamate containing 200,000 cpm L-[T- To separate GABA from glutamate, the mixture was applied to a 0.5-ml resin column prepared in a microfuge tube and centrifuged into a tube. The column was washed with 200 |xl ice-cold water. The radioactivity in the filtrate was compared with that in a sample without enzyme. Immunoprecipitation assays. Purified and enzymatically active pork GAD showed both isoforms (67,000 and 65,000 M r ) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This was confirmed by Western-blot analysis with a GA D-6 antibody (11) and by direct protein sequence analysis. The GAD was iodinated with 125 I to 90 ^Ci/ixg with chloramine T (12). Nonspecific reactivity with normal sera was reduced by preincubating the [ 125 I]GAD with pooled normal sera as follows. Control human serum (250 JJLI) was added to 2 x 10 6 cpm of labeled GAD in 400 IJLI wash buffer (20 mM Tris [pH 7.4], 150 mM NaCI, 0.5% Triton X-100 wt/vol). After 1 h on ice, 500 jxl of 50% protein A-Sepharose (Pharmacia) was added, the mixture was left on ice for 1 h, centrifuged, and the supernatant was removed. The protein A Sepharose was washed once with 600 jil wash buffer, and the supernatants containing [
125 I]GAD were pooled. For immunoprecipitation, 40 |xl [ 125 I]GAD (50,000 cpm) was added to 25 (xl test serum diluted 1:2 in cold wash buffer. The samples were left at 4°C overnight, and 50 |xl of 50% protein A Sepharose was added for 1 h at 4°C. The samples were centrifuged, the pellets were washed three times in 750 |xl wash buffer, and counted for radioactivity.
RESULTS

Immunoprecipitation of GAD.
The immunoprecipitation reaction was quantitated by including in each assay a positive reference serum from a patient with early diabetes, which was defined to contain 100 U reactivity. The activity of test sera was expressed as a percentage of the counts precipitated by the reference serum. Sera from nondiabetic blood donors were included with every assay. The interassay coefficient of variation (CV.) was 11% (n = 6), and the intra-assay CV. was 13% (n = 9). Although protein A-Sepharose was used routinely for precipitation of Igs, 10 sera were analyzed in duplicate with protein A Sepharose and protein G Sepharose with similar results. The mean ± SD antibody for the 55 nondiabetic blood donors was 7 ± 4 U. Sera were considered positive if they contained 20 U of antibody, which was 3SD above the mean of the control group. By this criterion, 50 (63%) of 80 patients with IDDM had antibodies to GAD; 69% of 26 patients with diabetes of short duration (0-12 mo) and 59% of 54 patients with diabetes of long duration (3-42 yr) had antibodies to GAD ( Table 1 ). The mean level of anti-GAD in the patients who gave a positive result was 74 ± 31 U, and the distribution of antibodies was similar in each group (Table 1) . Of the 20 NIDDM sera, one (5%) was positive at a borderline level (26 U). All 3 patients with unclassified diabetes had antibodies to GAD (81-102JDFU). Islet cell antibodies. ICA were present in 17 (21 %) of 80 patients with IDDM, 38% of 26 patients with early IDDM of known duration, and 13% of 54 patients with longduration IDDM; levels ranged from 5 to 320 JDF U. One patient with NIDDM had 5 JDFU ICA (Table 1) . ICA was present in 2 of the 3 patients with unclassified diabetes (5 and 40 JDF U, respectively). There was some concor- dance between anti-GAD and ICA ( Table 2 ). Note that ICA were less frequently demonstrable, particularly in long-duration cases of IDDM.
GAD AND DIABETES
DISCUSSION
The onset of IDDM is preceded by a clinically silent destruction of the pancreatic p-cells usually by an autoimmune process (2,13) serologically associated with autoantibodies to ICAs. These include the 64,000-M r protein, now recognized as GAD (3, 4) , the cytoplasmic ICA demonstrable by immunofluorescence (14) and insulin autoantibodies (15) . Antibody to the 64,000-/W r molecule has been extremely difficult to assay because of the need to prepare antigen from large quantities of islet cell preparations. However, with radioiodine-labeled GAD prepared from pig brain, the antibody could be readily and specifically detected by an immunoprecipitation assay. It is of interest that the 64,000-/W r antigen is an enzyme molecule pertaining to various disease-relevant autoantigens, most notably thyroid peroxidase in autoimmune thyroiditis (16) , H + K + ATPase in autoimmune gastritis (17) , and pyruvate dehydrogenase in primary biliary cirrhosis (18) . GAD is not species specific and, in fact, cDNAs for brain GAD from humans (19) , rat (20) , and cat (21) have such close homology that antibody reactivity could be expected with any mammalian GAD preparation. Also, the autoantigen is clearly not organ specific because our source was brain. However, we can note that the sequence of GAD from brain and pancreatic islets, the major sites in which GAD is demonstrable, appears to differ only by allelic variations (22, 23) . GAD exists as at least two isoforms (24) , and our preparation contained both representatives, as indicated by our data by PAGE.
The identification of the 64,000-/W r antigen as GAD and the development of simple assays for anti-GAD such as we have described should provide a valuable tool for diabetes research. Studies in progress in our laboratory on effects of serum volumes and incubation times could further optimize this assay. Note that anti-GAD is not a transient reactivity, unlike the sensitivity to the cytoplasmic antigen, because 60% of long-standing IDDM cases retained positivity. Similar data were reported for antibody to the 64,000-M r antigen (4). We note that 23% of sera from newly diagnosed cases of IDDM were negative for anti-GAD and cytoplasmic ICA. It will be of interest to make detailed comparisons between cases of acute IDDM that are positive or negative for anti-GAD to gain evidence of etiologic and/or serological heterogeneity.
The function of GAD in the pancreatic islet may relate to signaling between a-cells via the transmitter GABA (25) , the catalytic product of GAD. Just how GAD becomes implicated in the islet cell autoimmune reaction is unknown, as does the relationship of GAD to any putative islet cell cytoplasmic autoantigen. Interest will also be taken in the mapping of B-and T-cell epitopes in the GAD molecule as has been done for other recently identified enzyme autoantigens, with specific immunotherapy a reasonable expectation. Finally, the availability of simple assays for anti-GAD with purified brain prepa-
